Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-21558 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- HMBOX1 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant protein fragment
- Description
- Recommended positive controls: HeLa, HepG2, Molt-4, Raji.
- Concentration
- 1 mg/mL
Submitted references Cancer-secreted exosomal miR-1468-5p promotes tumor immune escape via the immunosuppressive reprogramming of lymphatic vessels.
Zhou C, Wei W, Ma J, Yang Y, Liang L, Zhang Y, Wang Z, Chen X, Huang L, Wang W, Wu S
Molecular therapy : the journal of the American Society of Gene Therapy 2021 Apr 7;29(4):1512-1528
Molecular therapy : the journal of the American Society of Gene Therapy 2021 Apr 7;29(4):1512-1528
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot using HMBOX1 Polyclonal Antibody (Product # PA5-21558). Sample (30 µg of whole cell lysate). Lane A: Raji. 10% SDS PAGE. HMBOX1 Polyclonal Antibody (Product # PA5-21558) diluted at 1:1,000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunocytochemistry-Immunofluorescence analysis of HMBOX1 was performed in HeLa cells fixed in 4% paraformaldehyde at RT for 15 min. Green: HMBOX1 Polyclonal Antibody (Product # PA5-21558) diluted at 1:500. Red: alpha Tubulin, a cytoskeleton marker. Blue: Hoechst 33342 staining.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of paraffin-embedded SW480 xenograft , using Homeobox-containing protein 1 (Product # PA5-21558) antibody at 1:500 dilution. Antigen Retrieval: EDTA based buffer, pH 8.0, 15 min.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6 miR-1468-5p directly targets HMBOX1 in HDLECs to suppress CD8 + T cell immunity (A) Target gene prediction of miR-1468-5p with two bioinformatics tools. (B) qRT-PCR analysis of predicted genes expression in HDLECs transfected with miR-1468-5p mimics or NC. (C) Western blot of HMBOX1 expression in HDLECs transfected with miR-1468-5p mimics or NC. (D) The wild type (WT) and a mutated type (MT) of binding site between miR-1468-5p and HMBOX1. (E) Relative luciferase activity of HDLECs with indicated treatments. (F and G) Flow cytometry analysis of PD-L1 expression (F) and quantification of tube formation (G) in HDLECs transfected with siHMBOX1 or siRNA. (H and I) Flow cytometry analysis of PD-L1 expression (H) and quantification of tube formation (I) in HDLECs treated with miR-1468-5p mimics or NC in the presence of HMBOX1 or vector. Scale bar, 10 mum. (J-M) Flow cytometry analysis of IFN-gamma (J), CD69 (K), PD-1 (L), and Annexin V (M) expression on CD8 + T cells co-cultured with HDLECs treated with miR-1468-5p mimics or NC in the presence of HMBOX1 or vector. The numeric values under the western blot bands represent the protein relative expression (the indicated protein/GAPDH). Error bars represent the mean +- SD of three independent experiments. *p < 0.05; ***p < 0.001.